Oncternal Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12230 El Camino Real Ste 300, San Diego,...Phone Number
(858) 434-1113Website
www.oncternal.comRevenue
<$5 MillionStock Symbol
ONCTIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1b clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in precliniRead more
Oncternal Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncternal Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Oncternal Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Oncternal Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Oncternal Therapeutics recently announced quarterly report
Check if Oncternal Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Oncternal Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Oncternal Therapeutics is spiking on competitors!
Click to see if Oncternal Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Oncternal Therapeutics
Recommended Actions
Find VP level buyers at Oncternal Therapeutics
Find 2 more new buyers
Compare Similar Companies to Oncternal Therapeutics
Compare insights from companies similar to Oncternal Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oncternal Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncternal Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncternal Therapeutics.
Oncternal Therapeutics financials insights
Gather financial insights about Oncternal Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$11.3M
2017
Series B
$18.4M
2020
Debt
$150K
Oncternal Therapeutics Tech Stack
A closer look at the technologies used by Oncternal Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Project
Award, Spending/Investment, Data Management, Financial Planning, Clinical Operations, Operations
Layoffs
Layoffs
Project
Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Oncternal Therapeutics News & Media
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which will remove Oncternal's securities from listing and registration on Nasdaq, and to subsequently deregister with the Securities and Exchange Commission (“SEC”). Nasdaq previously suspended the trading of Oncternal’s common stock on December 3, 2024 andOncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC).Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808
The company also discontinued its other clinical programs as well, which included small molecule and monoclonal antibody modalities.Oncternal stock crashes by 60% as it lays off staff and scraps trials - Clinical Trials Arena
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncternal Therapeutics
Sign Up For FreeTo access detailed company insights
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab,... Read More
